ERBB2 and neoplasm: In this analysis, patients with centrally assessed tumor HER2 IHC 3+ status in the primary cohort (n = 91) had higher ORR than those with HER2 IHC 2+/ISH+ status (n = 28; ORR (95% CI) 58.2% (47.4–68.5%) versus 28.6% (13.2–48.7%), respectively) (Fig. 2a).